Application of histone methyltransferase SETD2 as neuropathic pain drug target

The invention discloses an application of histone methyltransferase SETD2 as a neuropathic pain drug target. The SETD2 influences the excitability of peripheral neurons by regulating the expression of an NMDA receptor, and changes the sensitivity of an organism to a pain signal, so that the SETD2 po...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	GU PANYANG, YIN YUAN, DENG MEICHUN, CHEN GONG
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	AGRICULTURE ANIMAL HUSBANDRY BEER BIOCHEMISTRY CARE OF BIRDS, FISHES, INSECTS CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR COMPOSITIONS THEREOF CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES CULTURE MEDIA ENZYMOLOGY FISHING FORESTRY HUMAN NECESSITIES HUNTING HYGIENE MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING NEW BREEDS OF ANIMALS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TRAPPING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention discloses an application of histone methyltransferase SETD2 as a neuropathic pain drug target. The SETD2 influences the excitability of peripheral neurons by regulating the expression of an NMDA receptor, and changes the sensitivity of an organism to a pain signal, so that the SETD2 possibly becomes a target spot for diagnosing and treating pain symptom diseases. The invention provides a new pain symptom disease diagnosis and treatment target spot, a new mechanism of pathological pain is clarified, and compared with opioid drugs, non-steroidal anti-inflammatory drugs, antidepressant drugs and the like which are clinically used at present, the used drugs are lower in drug dependence and adverse drug reaction, higher in overall safety and stronger in pertinence. 本发明公开了组蛋白甲基转移酶SETD2作为神经病理性疼痛药物靶点的应用。本发明公开了SETD2通过调节NMDA受体表达从而影响外周神经元兴奋性，改变了机体对疼痛信号的敏感性，因此可能成为诊断以及治疗疼痛症状疾病的靶点。本发明提供了新的疼痛症状疾病诊断及治疗的靶点，阐明了病理性疼痛的新机制，使用的药物较目前临床在用的阿片类药物、非甾体类抗炎药、抗抑郁药物等，药物依赖与药物不良反应更低，整体安全性更高，针对性更强。